SrasV1, Main, Exploration, bibRecord, 004D81

Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs

Identifieur interne : 004D81 ( Main/Exploration ); précédent : 004D80; suivant : 004D82

Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs

Auteurs : Jonathan P. Wong [Canada] ; Les P. Nagata [Canada] ; Mary E. Christopher [Canada] ; Andres M. Salazar [États-Unis] ; Roderic M. K. Dale [États-Unis]

Source :

Vaccine [ 0264-410X ] ; 2005.

RBID : Pascal:06-0198136

Descripteurs français

KwdFr :
- Animaux, Carboxyméthylcellulose de sodium (administration et posologie), Carboxyméthylcellulose de sodium (analogues et dérivés), Carboxyméthylcellulose de sodium (pharmacologie), Encéphalomyélite équine (), Grippe humaine (), Humains, Ilots CpG, Infections de l'appareil respiratoire (), Liposomes, Maladies virales (), Oligodésoxyribonucléotides (administration et posologie), Oligodésoxyribonucléotides (pharmacologie), Poly I-C (administration et posologie), Poly I-C (pharmacologie), Polylysine (administration et posologie), Polylysine (analogues et dérivés), Polylysine (pharmacologie), Souris, Virus de l'encéphalite équine de l'Ouest, Virus de la grippe A.
MESH :
- administration et posologie : Carboxyméthylcellulose de sodium, Oligodésoxyribonucléotides, Poly I-C, Polylysine.
- analogues et dérivés : Carboxyméthylcellulose de sodium, Polylysine.
- pharmacologie : Carboxyméthylcellulose de sodium, Oligodésoxyribonucléotides, Poly I-C, Polylysine.
Pascal (Inist)
- Animaux, Chimioprophylaxie, Aigu, Acide nucléique, Encéphalomyélite équine, Grippe humaine, Humains, Ilots CpG, Infections de l'appareil respiratoire, Liposomes, Maladies virales, Souris, Virose, Virus de l'encéphalite équine de l'Ouest, Virus de la grippe A.

English descriptors

KwdEn :
- Acute, Animals, Carboxymethylcellulose Sodium (administration & dosage), Carboxymethylcellulose Sodium (analogs & derivatives), Carboxymethylcellulose Sodium (pharmacology), Chemoprophylaxis, CpG Islands, Encephalitis Virus, Western Equine, Encephalomyelitis, Equine (prevention & control), Humans, Influenza A virus, Influenza, Human (prevention & control), Liposomes, Mice, Nucleic acid, Oligodeoxyribonucleotides (administration & dosage), Oligodeoxyribonucleotides (pharmacology), Poly I-C (administration & dosage), Poly I-C (pharmacology), Polylysine (administration & dosage), Polylysine (analogs & derivatives), Polylysine (pharmacology), Respiratory Tract Infections (prevention & control), Viral disease, Virus Diseases (prevention & control).
MESH :
- chemical , administration & dosage : Carboxymethylcellulose Sodium, Oligodeoxyribonucleotides, Poly I-C, Polylysine.
- chemical , analogs & derivatives : Carboxymethylcellulose Sodium, Polylysine.
- chemical , pharmacology : Carboxymethylcellulose Sodium, Oligodeoxyribonucleotides, Poly I-C, Polylysine.
- prevention & control : Encephalomyelitis, Equine, Influenza, Human, Respiratory Tract Infections, Virus Diseases.
- Animals, CpG Islands, Encephalitis Virus, Western Equine, Humans, Influenza A virus, Liposomes, Mice.

Abstract

Acute respiratory virus infections such as SARS and pandemic influenza are highly contagious diseases that cause global crisis, and inflict severe human mortality and morbidity. Vaccines against these viruses are either unavailable or do not provide adequate protection. In the absence of effective vaccines, nucleic acid-based immunomodulators have the potential to offer effective, broad-spectrum protection against these deadly pathogens. Poly ICLC and CpG oligonucleotides are promising gene-based drugs which have been shown in animal studies to protect against acute respiratory virus infections. Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator. When encapsulated in liposomes, poly ICLC offers complete protection (100% survival rate in pretreated group versus 0% survival in control group) against a lethal respiratory challenge of influenza A virus in mice. This antiviral effect has been shown to persist for up to 3 weeks post-drug treatment. Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine. CpG oligos in liposomes also provided high level of protection against the lethal influenza challenge. Together, these studies suggest nucleic acid-based immunomodulators are promising antiviral agents which can offer effective and non-specific protection against acute respiratory virus infections.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs</title>
<author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P." last="Wong">Jonathan P. Wong</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1>
<s2>Suffield, Alherta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Defence R&D Canada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P." last="Nagata">Les P. Nagata</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1>
<s2>Suffield, Alherta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Defence R&D Canada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E." last="Christopher">Mary E. Christopher</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1>
<s2>Suffield, Alherta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Defence R&D Canada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M." last="Salazar">Andres M. Salazar</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oncovir Inc</s1>
<s2>Washington, DC</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M. K." last="Dale">Roderic M. K. Dale</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Oligos Etc. Inc</s1>
<s2>Wilsonville, OR</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0198136</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0198136 INIST</idno>
<idno type="RBID">Pascal:06-0198136</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000521</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000469</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000598</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000598</idno>
<idno type="wicri:doubleKey">0264-410X:2005:Wong J:prophylaxis:of:acute</idno>
<idno type="wicri:Area/Main/Merge">005118</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15755608</idno>
<idno type="wicri:Area/PubMed/Corpus">002855</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002855</idno>
<idno type="wicri:Area/PubMed/Curation">002855</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002855</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002570</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002570</idno>
<idno type="wicri:Area/Ncbi/Merge">000E19</idno>
<idno type="wicri:Area/Ncbi/Curation">000E19</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E19</idno>
<idno type="wicri:doubleKey">0264-410X:2005:Wong J:prophylaxis:of:acute</idno>
<idno type="wicri:Area/Main/Merge">004978</idno>
<idno type="wicri:Area/Main/Curation">004D81</idno>
<idno type="wicri:Area/Main/Exploration">004D81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs</title>
<author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P." last="Wong">Jonathan P. Wong</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1>
<s2>Suffield, Alherta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Defence R&D Canada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P." last="Nagata">Les P. Nagata</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1>
<s2>Suffield, Alherta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Defence R&D Canada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E." last="Christopher">Mary E. Christopher</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1>
<s2>Suffield, Alherta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Defence R&D Canada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M." last="Salazar">Andres M. Salazar</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oncovir Inc</s1>
<s2>Washington, DC</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M. K." last="Dale">Roderic M. K. Dale</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Oligos Etc. Inc</s1>
<s2>Wilsonville, OR</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term>
<term>Animals</term>
<term>Carboxymethylcellulose Sodium (administration & dosage)</term>
<term>Carboxymethylcellulose Sodium (analogs & derivatives)</term>
<term>Carboxymethylcellulose Sodium (pharmacology)</term>
<term>Chemoprophylaxis</term>
<term>CpG Islands</term>
<term>Encephalitis Virus, Western Equine</term>
<term>Encephalomyelitis, Equine (prevention & control)</term>
<term>Humans</term>
<term>Influenza A virus</term>
<term>Influenza, Human (prevention & control)</term>
<term>Liposomes</term>
<term>Mice</term>
<term>Nucleic acid</term>
<term>Oligodeoxyribonucleotides (administration & dosage)</term>
<term>Oligodeoxyribonucleotides (pharmacology)</term>
<term>Poly I-C (administration & dosage)</term>
<term>Poly I-C (pharmacology)</term>
<term>Polylysine (administration & dosage)</term>
<term>Polylysine (analogs & derivatives)</term>
<term>Polylysine (pharmacology)</term>
<term>Respiratory Tract Infections (prevention & control)</term>
<term>Viral disease</term>
<term>Virus Diseases (prevention & control)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Carboxyméthylcellulose de sodium (administration et posologie)</term>
<term>Carboxyméthylcellulose de sodium (analogues et dérivés)</term>
<term>Carboxyméthylcellulose de sodium (pharmacologie)</term>
<term>Encéphalomyélite équine ()</term>
<term>Grippe humaine ()</term>
<term>Humains</term>
<term>Ilots CpG</term>
<term>Infections de l'appareil respiratoire ()</term>
<term>Liposomes</term>
<term>Maladies virales ()</term>
<term>Oligodésoxyribonucléotides (administration et posologie)</term>
<term>Oligodésoxyribonucléotides (pharmacologie)</term>
<term>Poly I-C (administration et posologie)</term>
<term>Poly I-C (pharmacologie)</term>
<term>Polylysine (administration et posologie)</term>
<term>Polylysine (analogues et dérivés)</term>
<term>Polylysine (pharmacologie)</term>
<term>Souris</term>
<term>Virus de l'encéphalite équine de l'Ouest</term>
<term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboxymethylcellulose Sodium</term>
<term>Oligodeoxyribonucleotides</term>
<term>Poly I-C</term>
<term>Polylysine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Carboxymethylcellulose Sodium</term>
<term>Polylysine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Carboxymethylcellulose Sodium</term>
<term>Oligodeoxyribonucleotides</term>
<term>Poly I-C</term>
<term>Polylysine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Carboxyméthylcellulose de sodium</term>
<term>Oligodésoxyribonucléotides</term>
<term>Poly I-C</term>
<term>Polylysine</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Carboxyméthylcellulose de sodium</term>
<term>Polylysine</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Carboxyméthylcellulose de sodium</term>
<term>Oligodésoxyribonucléotides</term>
<term>Poly I-C</term>
<term>Polylysine</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Encephalomyelitis, Equine</term>
<term>Influenza, Human</term>
<term>Respiratory Tract Infections</term>
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>CpG Islands</term>
<term>Encephalitis Virus, Western Equine</term>
<term>Humans</term>
<term>Influenza A virus</term>
<term>Liposomes</term>
<term>Mice</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Chimioprophylaxie</term>
<term>Aigu</term>
<term>Acide nucléique</term>
<term>Encéphalomyélite équine</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Ilots CpG</term>
<term>Infections de l'appareil respiratoire</term>
<term>Liposomes</term>
<term>Maladies virales</term>
<term>Souris</term>
<term>Virose</term>
<term>Virus de l'encéphalite équine de l'Ouest</term>
<term>Virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Acute respiratory virus infections such as SARS and pandemic influenza are highly contagious diseases that cause global crisis, and inflict severe human mortality and morbidity. Vaccines against these viruses are either unavailable or do not provide adequate protection. In the absence of effective vaccines, nucleic acid-based immunomodulators have the potential to offer effective, broad-spectrum protection against these deadly pathogens. Poly ICLC and CpG oligonucleotides are promising gene-based drugs which have been shown in animal studies to protect against acute respiratory virus infections. Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator. When encapsulated in liposomes, poly ICLC offers complete protection (100% survival rate in pretreated group versus 0% survival in control group) against a lethal respiratory challenge of influenza A virus in mice. This antiviral effect has been shown to persist for up to 3 weeks post-drug treatment. Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine. CpG oligos in liposomes also provided high level of protection against the lethal influenza challenge. Together, these studies suggest nucleic acid-based immunomodulators are promising antiviral agents which can offer effective and non-specific protection against acute respiratory virus infections.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>District de Columbia</li>
<li>Oregon</li>
</region>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P." last="Wong">Jonathan P. Wong</name>
</noRegion>
<name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E." last="Christopher">Mary E. Christopher</name>
<name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P." last="Nagata">Les P. Nagata</name>
</country>
<country name="États-Unis"><region name="District de Columbia"><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M." last="Salazar">Andres M. Salazar</name>
</region>
<name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M. K." last="Dale">Roderic M. K. Dale</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D81 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D81 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:06-0198136
   |texte=   Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs

Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.